Oral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit Thrombosis - ORBIT

Description:

ORBIT was a multicenter, placebo-controlled, randomized clinical trial to investigate the efficacy and safety of the oral glycoprotein IIb/IIIa antagonist Xemilofiban administered after percutaneous coronary intervention (PCI).